<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348438</url>
  </required_header>
  <id_info>
    <org_study_id>ENG CIP-001</org_study_id>
    <nct_id>NCT01348438</nct_id>
  </id_info>
  <brief_title>Transapical Implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System - The Engager European Pivotal Trial</brief_title>
  <official_title>Transapical Implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System - The Engager European Pivotal Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and clinical performance of the Engager&#xD;
      Transcatheter Aortic Valve Implantation System in patients with severe aortic valve stenosis&#xD;
      who are at high risk for surgical valve replacement.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2011</start_date>
  <completion_date type="Actual">January 25, 2018</completion_date>
  <primary_completion_date type="Actual">February 28, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 Days</time_frame>
    <description>All-cause mortality within 30 days post-implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) free survival at 30 days and 6 months post implantation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device and procedure related Major Adverse Events</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Single arm study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic Engager Transcatheter Aortic Valve Implantation System</intervention_name>
    <description>Transapical implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System</description>
    <arm_group_label>Single arm study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Severe aortic stenosis defined as one or more of the following by Doppler&#xD;
             echocardiography: mean gradient &gt; 40 mmHg; max velocity &gt; 4m/s; aortic valve area ≤&#xD;
             0.8 cm2.&#xD;
&#xD;
          2. Symptoms related to aortic valve disease, and NYHA Functional Class II or greater.&#xD;
&#xD;
          3. Logistic EuroSCORE predicted risk for mortality of ≥20%, or comorbidity judged by the&#xD;
             investigator to pose an absolute or relative contraindication for conventional aortic&#xD;
             valve replacement.&#xD;
&#xD;
          4. Patient is indicated for aortic valve implantation with a biological prosthesis&#xD;
             (tissue valve) in accordance with the 2007 European Society of Cardiology (ESC)&#xD;
             Guidelines for management of valvular heart disease.&#xD;
&#xD;
          5. Age ≥ 18 years.&#xD;
&#xD;
          6. Echocardiographically determined aortic annulus diameter of ≥19 mm and ≤ 26 mm in a&#xD;
             long-axis view.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Congenital unicuspid or bicuspid aortic valve.&#xD;
&#xD;
          2. Severe eccentricity of calcification, defined as calcium deposits larger than 6mm in&#xD;
             diameter.&#xD;
&#xD;
          3. Echocardiographic evidence of intracardiac mass, thrombus, or vegetation.&#xD;
&#xD;
          4. Left ventricular ejection fraction &lt; 25%, as determined by contrast ventriculography,&#xD;
             or echocardiography or radionuclide angiography if contrast ventriculography not&#xD;
             available&#xD;
&#xD;
          5. Hypertrophic obstructive cardiomyopathy.&#xD;
&#xD;
          6. Patients with life expectancy less than 12 months due to an underlying non-cardiac&#xD;
             comorbid disease.&#xD;
&#xD;
          7. Known hypersensitivity or contraindication that cannot be adequately controlled with&#xD;
             pre-medication to any study medication or material, such as contrast medium or&#xD;
             Nitinol.&#xD;
&#xD;
          8. Sepsis or acute endocarditis.&#xD;
&#xD;
          9. Blood dyscrasia such as acute anemia, leucopenia, or thrombocytopenia; bleeding&#xD;
             diathesis, or coagulopathy.&#xD;
&#xD;
         10. Renal insufficiency assessed by creatinine &gt; 2.5 mg/dl and/or end stage renal disease&#xD;
             requiring chronic dialysis.&#xD;
&#xD;
         11. Active peptic ulcer or GI bleeding within 3 months from the planned index procedure.&#xD;
&#xD;
         12. Untreated clinically significant coronary artery disease requiring revascularization.&#xD;
&#xD;
         13. Cardiogenic shock, suspected cardiogenic shock, or hemodynamic instability requiring&#xD;
             inotropic support or mechanical heart assistance.&#xD;
&#xD;
         14. Significant aortic disease, including abdominal and thoracic aortic aneurysm, defined&#xD;
             as maximal luminal diameter of 5 cm or greater.&#xD;
&#xD;
         15. Need for emergency surgery, cardiac or non-cardiac.&#xD;
&#xD;
         16. History of myocardial infarction in the last 6 weeks.&#xD;
&#xD;
         17. History of TIA or CVA in the last 6 months.&#xD;
&#xD;
         18. Therapeutic invasive cardiac procedure, with the exception of aortic balloon&#xD;
             valvuloplasty, performed within 30 days of the planned date of valve implantation, or&#xD;
             6 months in the case of drug-eluting stents.&#xD;
&#xD;
         19. Pre-existing prosthetic heart valve or prosthetic ring in any position.&#xD;
&#xD;
         20. Mitral regurgitation greater than 2+ by angiography or moderate by echocardiography.&#xD;
&#xD;
         21. Patient refuses a blood transfusion.&#xD;
&#xD;
         22. Patient is currently enrolled in another investigational device or drug trial that may&#xD;
             influence the outcome of this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volkmar Falk, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Louis Vanoverschelde, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires Saint-Luc, Brussels</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint- Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhr-Universität Bochum</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln Heart Center</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg- Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Zurich - Klinik für Herzchirurgie, UniversitätsSpital</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 4, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <last_update_submitted>September 14, 2018</last_update_submitted>
  <last_update_submitted_qc>September 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high risk</keyword>
  <keyword>surgical valve replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

